| scholarly article | Q13442814 |
| P2093 | author name string | A Belluzzi | |
| A Pera | |||
| C Brignola | |||
| M Campieri | |||
| M Miglioli | |||
| S Boschi | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fish | Q152 |
| Crohn's disease | Q1472 | ||
| P304 | page(s) | 1557-60 | |
| P577 | publication date | 1996-06-13 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease | |
| P478 | volume | 334 |
| Q44504763 | A biomarker of n-3 compliance in patients taking fish oil for rheumatoid arthritis |
| Q44006209 | A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis |
| Q33857617 | A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response |
| Q35365913 | A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease |
| Q34560319 | A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease |
| Q37060108 | A review of complementary and alternative approaches to immunomodulation |
| Q92579832 | A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease |
| Q37866342 | A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia |
| Q35550952 | A simple method of supplementation of omega-3 polyunsaturated fatty acids: use of fortified yogurt in healthy volunteers. |
| Q47102876 | Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases |
| Q83468592 | Acute pancreatitis in obesity: adipokines and dietary fish oil |
| Q77091149 | Adjuvant post-operative therapy |
| Q34069427 | Alternative medicines as emerging therapies for inflammatory bowel diseases |
| Q40132979 | An arachidonic acid-enriched diet does not result in more colonic inflammation as compared with fish oil- or oleic acid-enriched diets in mice with experimental colitis |
| Q36122829 | An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part II. |
| Q38370798 | An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases. |
| Q41890935 | Antagonist: Crohn's disease recurrence can be prevented after ileal resection |
| Q42756142 | Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal |
| Q44318829 | Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial |
| Q42982060 | Antioxidants and mucosa protectives: realistic therapeutic options in inflammatory bowel disease? |
| Q40111828 | Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells |
| Q33967202 | Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease |
| Q36165341 | Bone turnover and nutritional status in Crohn's disease: relationship to circulating mononuclear cell function and response to fish oil and antioxidants |
| Q37205414 | Bowel rest and nutrition therapy in the management of active Crohn's disease |
| Q42589189 | Carbohydrate Elimination or Adaptation Diet for Symptoms of Intestinal Discomfort in IBD: Rationales for "Gibsons' Conundrum". |
| Q21131205 | Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics |
| Q43160001 | Change in the fatty acid pattern of erythrocyte membrane phospholipids after oral supplementation of specific fatty acids in patients with gastrointestinal diseases |
| Q37613463 | Chemotherapeutic Properties of n-3 Polyunsaturated Fatty Acids - Old Concepts and New Insights. |
| Q45948702 | Cholesterol metabolism in active Crohn's disease. |
| Q46568948 | Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. |
| Q38176485 | Colorectal disorders: A dietary management perspective |
| Q35196243 | Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis |
| Q39017126 | Comment On: Maintenance of Remission in Inflammatory Bowel Disease Using Omega-3 Fatty Acids (Fish Oil): A Systematic Review and Meta-Analyses |
| Q53968303 | Complementary and Alternative Medicine. |
| Q34363569 | Complementary and alternative medicine: assessing the evidence for immunological benefits |
| Q55024890 | Comprehensive Nutritional and Dietary Intervention for Autism Spectrum Disorder-A Randomized, Controlled 12-Month Trial. |
| Q33719500 | Contributions of neutrophils to resolution of mucosal inflammation |
| Q83851713 | Crohn's disease |
| Q77091123 | Crohn's disease: nutrition and nutritional therapy |
| Q36548128 | Current clinical applications of omega-6 and omega-3 fatty acids |
| Q43073013 | Current medical therapy of inflammatory bowel disease. |
| Q55383256 | De novo transcriptome assembly of the eight major organs of Sacha Inchi (Plukenetia volubilis) and the identification of genes involved in α-linolenic acid metabolism. |
| Q41654307 | Diet and nutrition in primary care. From antioxidants to zinc |
| Q22251396 | Dietary and nutritional considerations for inflammatory bowel disease |
| Q73495746 | Dietary docosahexaenoic acid suppresses inflammation and immunoresponses in contact hypersensitivity reaction in mice |
| Q37370591 | Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. |
| Q34317617 | Dietary fat intake and inflammatory bowel disease |
| Q47672700 | Dietary fish oil diminishes lymphocyte adhesion to macrophage and endothelial cell monolayers |
| Q39201298 | Dietary lipids and sweeteners regulate glucagon-like peptide-2 secretion. |
| Q91891813 | Dietary lipids fuel GPX4-restricted enteritis resembling Crohn's disease |
| Q35150616 | Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis |
| Q45126689 | Dietary oils modify the host immune response and colonic tissue damage following Citrobacter rodentium infection in mice. |
| Q58745942 | Dietary practices and inflammatory bowel disease |
| Q57112601 | Diets rich in n-6 PUFA induce intestinal microbial dysbiosis in aged mice |
| Q46522890 | Docosahexaenoic acid changes lipid composition and interleukin-2 receptor signaling in membrane rafts |
| Q47995264 | EPA blocks TNF-α-induced inhibition of sugar uptake in Caco-2 cells via GPR120 and AMPK. |
| Q38164067 | Effect of dietary fat on intestinal inflammatory diseases |
| Q46120318 | Effect of dietary fatty acid composition on Th1/Th2 polarization in lymphocytes |
| Q40467967 | Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis |
| Q50229900 | Effect of oral eicosapentaenoic acid on epidermal Langerhans cell numbers and PGD2 production in UVR-exposed human skin: a randomised controlled study. |
| Q57178306 | Effects of Fish Oil on HIV-Related Inflammation and Markers of Immunosenescence: A Randomized Clinical Trial |
| Q92990866 | Effects of Fish n-3 PUFAs on Intestinal Microbiota and Immune System |
| Q47260247 | Effects of Omega-3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue |
| Q44279977 | Effects of duodenal seal oil administration in patients with inflammatory bowel disease |
| Q33747102 | Effects of food on clinical pharmacokinetics |
| Q74326651 | Eicosapentaenoic and docosahexaenoic acids alter rat spleen leukocyte fatty acid composition and prostaglandin E2 production but have different effects on lymphocyte functions and cell-mediated immunity |
| Q39980648 | Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid |
| Q24299225 | Endoplasmic reticulum stress-activated C/EBP homologous protein enhances nuclear factor-kappaB signals via repression of peroxisome proliferator-activated receptor gamma |
| Q37240742 | Enhanced absorption of n-3 fatty acids from emulsified compared with encapsulated fish oil |
| Q74741464 | Enteral nutrition |
| Q46612631 | Essential fatty acid depletion in children with inflammatory bowel disease |
| Q44563339 | Essential fatty acid status in paediatric Crohn's disease: relationship with disease activity and nutritional status. |
| Q34538014 | Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective |
| Q34564902 | European evidence based consensus on the diagnosis and management of Crohn's disease: current management. |
| Q22242050 | European evidence based consensus on the diagnosis and management of Crohn's disease: special situations |
| Q35216827 | Evaluation of new therapies for inflammatory bowel disease |
| Q42243859 | Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function |
| Q27021694 | Experimental evidence of ω-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases |
| Q77407476 | Fatty acid composition of 19 species of fish from the Black Sea and the Marmara Sea |
| Q37642866 | Fatty acids and immune function: relevance to inflammatory bowel diseases. |
| Q35171522 | Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3. |
| Q35878818 | Fish Oil-Rich Diet Promotes Hematopoiesis and Alters Hematopoietic Niche. |
| Q34584247 | Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis |
| Q27337413 | Fish oil enhances recovery of intestinal microbiota and epithelial integrity in chronic rejection of intestinal transplant |
| Q46529344 | Fish oil fix. |
| Q36101767 | Fish oil in cardiovascular prevention. |
| Q34986662 | Fish oil in primary and secondary cardiovascular prevention |
| Q21195667 | Fish oil: what the prescriber needs to know |
| Q57971637 | From metagenomic data to personalized in silico microbiotas: predicting dietary supplements for Crohn's disease |
| Q30311923 | Future therapies for inflammatory bowel disease |
| Q35105502 | Gene polymorphisms, inflammatory diseases and cancer |
| Q35909254 | Health implications of high dietary omega-6 polyunsaturated Fatty acids. |
| Q37372932 | Idiopathic inflammatory bowel disease in cats. Rational treatment selection |
| Q38099615 | Immunometabolic role of long-chain omega-3 fatty acids in obesity-induced inflammation |
| Q35939357 | Immunomodulatory action of dietary fish oil and targeted deletion of intestinal epithelial cell PPARδ in inflammation-induced colon carcinogenesis |
| Q74822299 | Immunonutrition: the pediatric experience |
| Q35225804 | Impact of EPA ingestion on COX- and LOX-mediated eicosanoid synthesis in skin with and without a pro-inflammatory UVR challenge--report of a randomised controlled study in humans |
| Q37182945 | Importance of nutrition in inflammatory bowel disease |
| Q54395066 | In vitro effects of food extracts on selected probiotic and pathogenic bacteria. |
| Q40004097 | Increased basolateral sorting of carcinoembryonic antigen in a polarized colon carcinoma cell line after cholesterol depletion-Implications for treatment of inflammatory bowel disease |
| Q57496206 | Inflammation and intestinal leakiness in older HIV+ individuals with fish oil treatment |
| Q39407229 | Inflammatory Bowel Disease in Children |
| Q77453637 | Inflammatory bowel disease |
| Q29615500 | Inflammatory bowel disease |
| Q33662060 | Inflammatory bowel disease in pediatric and adolescent patients |
| Q40906359 | Inflammatory bowel disease management. Some thoughts on future drug developments |
| Q21957029 | Inflammatory bowel disease: clinical aspects and established and evolving therapies |
| Q74528192 | Inflammatory bowel disease: short- and long-term treatments |
| Q37544889 | Inflammatory disease processes and interactions with nutrition |
| Q46121484 | Ingested matter affects intestinal lesions in Crohn's disease. |
| Q35081219 | Inhibition of leukocyte-endothelial interactions by oxidized omega-3 fatty acids: a novel mechanism for the anti-inflammatory effects of omega-3 fatty acids in fish oil. |
| Q36836131 | Inhibitory effects of omega-3 fatty acids on injury-induced epidermal growth factor receptor transactivation contribute to delayed wound healing |
| Q37345889 | Integrative medicine in gastrointestinal disease: evaluating the evidence |
| Q35653374 | Interactions between Diet, Bile Acid Metabolism, Gut Microbiota, and Inflammatory Bowel Diseases |
| Q24240542 | Interventions for prevention of post-operative recurrence of Crohn's disease |
| Q79853934 | Is omega-3 key to unlocking inflammation in obesity? |
| Q37205419 | Is there a role for bowel rest in nutrition management of Crohn's disease? |
| Q38230462 | Is there a role for fish oil in inflammatory bowel disease? |
| Q44005252 | LAT displacement from lipid rafts as a molecular mechanism for the inhibition of T cell signaling by polyunsaturated fatty acids |
| Q47608070 | Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status. |
| Q89951831 | Lego-inspired Capsular Devices for the Development of Personalized Dietary Supplements: Proof of Concept With Multimodal Release of Caffeine |
| Q33879437 | Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet |
| Q34162365 | Lipid modulation and systemic inflammation |
| Q36722118 | Lipoxins and resolvins in inflammatory bowel disease |
| Q38151841 | Long-chain omega-3 fatty acids: time to establish a dietary reference intake |
| Q27028080 | Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties |
| Q74649133 | Low levels of eicosapentaenoic and docosahexaenoic acids mimic the effects of fish oil upon rat lymphocytes |
| Q36175781 | Macronutrients and bioactive molecules: is there a specific role in the management of inflammatory bowel disease? |
| Q91937728 | Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD |
| Q35771490 | Maintenance of remission in Crohn's disease: current and emerging therapeutic options |
| Q34620794 | Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses |
| Q33785519 | Management of Crohn's disease. |
| Q35519195 | Management of inflammatory bowel disease |
| Q35091730 | Marine bioactives as functional food ingredients: potential to reduce the incidence of chronic diseases |
| Q38681602 | Marine natural products with anti-inflammatory activity |
| Q34161820 | Medical therapy for Crohn's disease: the state of the art. |
| Q33662010 | Medical therapy for inflammatory bowel disease |
| Q40793533 | Medium-chain fatty acids stimulate interleukin-8 production in Caco-2 cells with different mechanisms from long-chain fatty acids |
| Q73386844 | Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there? |
| Q34305750 | Modulation of human immune and inflammatory responses by dietary fatty acids |
| Q41686763 | Multivariate identification of metabolic features in inflammatory bowel disease |
| Q34893006 | N-3 fatty acids for the treatment of inflammatory bowel diseases |
| Q38634215 | New treatments for inflammatory bowel disease |
| Q34516769 | Newer components of enteral formulas |
| Q36181229 | Novel approaches to inflammatory bowel disease |
| Q35670502 | Novel pituitary ligands: peroxisome proliferator activating receptor-gamma |
| Q33662018 | Novel therapies for inflammatory bowel disease |
| Q35646449 | Nutraceutical Supplements for Inflammatory Bowel Disease |
| Q22250970 | Nutrition and adult inflammatory bowel disease |
| Q33662052 | Nutrition and inflammatory bowel disease |
| Q26748785 | Nutrition in Pediatric Inflammatory Bowel Disease: From Etiology to Treatment. A Systematic Review |
| Q33541787 | Nutrition in inflammatory bowel disease |
| Q38225147 | Nutrition in pelvic radiation disease and inflammatory bowel disease: similarities and differences. |
| Q31048872 | Nutrition support in clinical practice: review of published data and recommendations for future research directions |
| Q36863201 | Nutrition support in clinical practice: review of published data and recommendations for future research directions. National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition |
| Q61448103 | Nutritional Modulation of Immune Function: Analysis of Evidence, Mechanisms, and Clinical Relevance |
| Q38956740 | Nutritional Strategies in the Management of Adult Patients with Inflammatory Bowel Disease: Dietary Considerations from Active Disease to Disease Remission |
| Q80101346 | Nutritional Therapy in Inflammatory Bowel Disease |
| Q74256109 | Nutritional Treatments in Inflammatory Bowel Disease |
| Q26741389 | Nutritional concerns in pediatric inflammatory bowel disease |
| Q37763081 | Nutritional considerations in pediatric inflammatory bowel disease |
| Q74741483 | Nutritional issues in inflammatory bowel disease |
| Q41060588 | Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence |
| Q42704404 | Nutritional modulation of the inflammatory response in inflammatory bowel disease--from the molecular to the integrative to the clinical |
| Q40862477 | Nutritional therapy in Crohn's disease |
| Q24200184 | Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease |
| Q24241348 | Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease |
| Q24245394 | Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease |
| Q24245810 | Omega 3 fatty acids for prevention and treatment of cardiovascular disease |
| Q26798057 | Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed Evidence |
| Q37142087 | Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia |
| Q38010560 | Omega-3 fatty acids and inflammatory bowel diseases - a systematic review |
| Q46592166 | Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts |
| Q24201333 | Omega-3 fatty acids for intermittent claudication |
| Q24243172 | Omega-3 fatty acids for intermittent claudication |
| Q24247472 | Omega-3 fatty acids for intermittent claudication |
| Q55919856 | Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease |
| Q89958068 | Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease |
| Q90307768 | Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease |
| Q57311404 | Omega-3 fatty acids in wild plants, nuts and seeds |
| Q46818058 | Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids |
| Q36796125 | Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance |
| Q45903207 | Omega-3 poly-unsaturated fatty acids for the prevention of severe neutropenic enterocolitis in patients with acute myeloid leukemia. |
| Q36620178 | Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? |
| Q93074634 | Omega-3 polyunsaturated fatty acids attenuate inflammatory activation and alter differentiation in human adipocytes |
| Q31804370 | Omega-3 polyunsaturated fatty acids in adolescents: knowledge and consumption |
| Q98771358 | Opening a Window on Attention: Adjuvant Therapies for Inflammatory Bowel Disease |
| Q38530433 | Oral Diets and Nutrition Support for Inflammatory Bowel Disease: What Is the Evidence? |
| Q49387085 | PUFAs and IBD: Is There a Relationship? |
| Q53324592 | Patterns of complementary and alternative medicine use in a population of pediatric patients with inflammatory bowel disease. |
| Q73237036 | Pediatric Inflammatory Bowel Disease |
| Q63314207 | Plasma and mucosal fatty acid pattern in colectomized ulcerative colitis patients |
| Q46679615 | Polyunsaturated eicosapentaenoic acid changes lipid composition in lipid rafts |
| Q43699007 | Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. |
| Q35005053 | Polyunsaturated fatty acids and inflammatory diseases. |
| Q36741311 | Polyunsaturated fatty acids and membrane organization: elucidating mechanisms to balance immunotherapy and susceptibility to infection |
| Q36288228 | Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-insoluble membrane domains |
| Q54042664 | Polyunsaturated fatty acids reduce non-receptor-mediated transcellular permeation of protein across a model of intestinal epithelium in vitro. |
| Q36325184 | Postoperative management of ulcerative colitis and Crohn's disease |
| Q37914790 | Postoperative recurrent luminal Crohn's disease: a systematic review |
| Q37992788 | Potential value of nutrigenomics in Crohn's disease |
| Q50134207 | Production of lipid mediators across different disease stages of dextran sulfate sodium-induced colitis in mice. |
| Q46967684 | Protective effect of n-3 polyunsaturated fatty acid on primary culture of rat hepatocytes |
| Q36328401 | Protein palmitoylation in signal transduction of hematopoietic cells |
| Q35151307 | Pulmonary delivery of docosahexaenoic acid mitigates bleomycin-induced pulmonary fibrosis |
| Q77330990 | Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease |
| Q34188405 | Recent advances in inflammatory bowel disease |
| Q36968175 | Recent advances in the medical therapy of Crohn's disease in childhood |
| Q80101350 | Refractory Inflammatory Bowel Disease |
| Q38976720 | Regulation of T cell signalling by membrane lipids |
| Q34564516 | Regulatory potential of n-3 fatty acids in immunological and inflammatory processes |
| Q34759733 | Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis |
| Q33785525 | Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis |
| Q85020441 | Review |
| Q34669237 | Review article: Crohn's disease--the role of nutritional therapy |
| Q33445163 | Review article: diet and inflammatory bowel disease--epidemiology and treatment. |
| Q34141413 | Review: the role of omega 3 fatty acids in intestinal inflammation |
| Q59497127 | Role of Omega-6 and Omega-3 Fatty Acids in Inflammatory Bowel Disease |
| Q37718141 | Role of diet in the management of inflammatory bowel disease |
| Q35785440 | Role of omega-3 fatty acid supplementation in inflammation and malignancy |
| Q36648133 | Seafood consumption and components for health |
| Q73454372 | Serum n3 polyunsaturated fatty acids are depleted in Crohn's disease |
| Q34646398 | Short-term duodenal seal oil administration normalised n-6 to n-3 fatty acid ratio in rectal mucosa and ameliorated bodily pain in patients with inflammatory bowel disease |
| Q46489976 | Site specific delivery of microencapsulated fish oil to the gastrointestinal tract of the rat. |
| Q64070276 | Systematic review: outcomes and adverse events from randomised trials in Crohn's disease |
| Q35877619 | Targeting Therapy in Pediatric Inflammatory Bowel Disease |
| Q47367020 | The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives |
| Q35960415 | The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid |
| Q54558487 | The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man. |
| Q41763568 | The effect of omega-3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients |
| Q35688144 | The effects of an oral supplement enriched with fish oil, prebiotics, and antioxidants on nutrition status in Crohn's disease patients |
| Q44078613 | The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts. |
| Q28244071 | The organization, promoter analysis, and expression of the human PPARgamma gene |
| Q36289548 | The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes |
| Q35216463 | The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats |
| Q46797456 | The relationship between folate and docosahexaenoic acid in men. |
| Q33670800 | The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. |
| Q34532557 | The role of fish oils in the treatment of rheumatoid arthritis |
| Q37693240 | The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA. |
| Q34152778 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations |
| Q34178830 | The {omega}-3 fatty acid eicosapentaenoic acid elicits cAMP generation in colonic epithelial cells via a "store-operated" mechanism |
| Q37522903 | Therapeutic potential of n-3 polyunsaturated fatty acids in disease |
| Q34983954 | Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis |
| Q42641578 | Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease |
| Q36496776 | Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study |
| Q42536942 | Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier--implications for use of glucosamine in inflammatory disorders |
| Q74451125 | [1997 gastroenterology update--I] |
| Q82974598 | [Nutritional therapy in inflammatory bowel disease] |
| Q79133097 | [Role of dietary lipids in the mechanisms of inflammation, proliferation, differentiation and cell death in the gastrointestinal tract] |
| Q35542194 | n-3 Polyunsaturated fatty acids, inflammation and obesity-related disease |
| Q36328338 | n-3 polyunsaturated fatty acids suppress CD4(+) T cell proliferation by altering phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] organization |
Search more.